Skip to main content
Premium Trial:

Request an Annual Quote

Waters Nearly Doubles Q3 Profit, Revenues Increase 10 Percent

NEW YORK (GenomeWeb News) - Waters today reported a 10 percent increase in revenues and nearly doubled net income for the third quarter of 2005.
The mass spectrometry, chromatography and software company posted net income of $50.4 million for the quarter ended Sept. 30 –- a 96-percent increase over $25 million last year.
Total revenue rose to $300 million from $273 million in the third quarter of 2005.
Company chairman, president, and CEO Douglas Berthiaume credited the revenue increase to improved pharmaceutical spending in the US, expanding sales in Asia, efficient operations, and “overall positive acceptance and uptake” of the company's Acquity UPLC system. 
R&D spending rose to $19.1 million from $17 million in the prior-year period.
As of Sept. 30, Waters had $511.6 million in cash and cash equivalents.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more